» Articles » PMID: 22496707

The Effects of Transurethral Resection of the Prostate on Morbidity and Mortality in Patients with Nondialysis-requiring Renal Insufficiency

Overview
Journal Ther Adv Urol
Publisher Sage Publications
Date 2012 Apr 13
PMID 22496707
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To compare the prevalence of preoperative co-morbid factors and complications of transurethral resection of prostate (TUR-P) in patients with normal and non-dialysis requiring elevated serum creatinine levels.

Methods: The records of 357 consecutive patients with IPSS≥20, serum creatinine level ≤ 3 mg/dl, residual urine volume ≤ 300 ml and with no upper urinary tract dilatation or evidence of prostate cancer that underwent TUR-P were retrospectively evaluated. 60 patients who did not fulfill the inclusion criteria were excluded. The preoperative Na, K, creatinine levels and the early changes observed in these parameters after TUR-P of the patients with normal (Group1, n = 272) and elevated (Group2, n = 25) serum creatinine levels, as well as the preoperative baseline data and postoperative complications were compared.

Results: Preoperative PSA, serum urea, creatinine and K levels were significantly higher in group2. No significant differences were observed between early and late postoperative complications of the two groups. Co-morbid diseases were significantly more common in group2. No progression in renal failure or de novo need for hemodialysis was observed in group2.

Conclusions: TUR-P can be safely performed in BPH patients with mild serum creatinine elevations (1.6-3 mg/dl) and moderately increased prostate volumes without additional morbidity and mortality.

References
1.
Koch W, Ezz el Din K, de Wildt M, Debruyne F, de la Rosette J . The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol. 1996; 155(1):186-9. View

2.
HOLTGREWE H, VALK W . Factors influencing the mortality and morbidity of transurethral prostatectomy: a study of 2,015 cases. J Urol. 1962; 87:450-9. DOI: 10.1016/S0022-5347(17)64980-2. View

3.
Ekman P . BPH epidemiology and risk factors. Prostate Suppl. 1989; 2:23-31. DOI: 10.1002/pros.2990150505. View

4.
Sacks S, Aparicio S, Bevan A, Oliver D, Will E, Davison A . Late renal failure due to prostatic outflow obstruction: a preventable disease. BMJ. 1989; 298(6667):156-9. PMC: 1835497. DOI: 10.1136/bmj.298.6667.156. View

5.
McConnell J, Barry M, Bruskewitz R . Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin. 1994; (8):1-17. View